176 related articles for article (PubMed ID: 33218896)
1. Synthesis and structure-activity relationship of coumarins as potent Mcl-1 inhibitors for cancer treatment.
Xia YL; Wang JJ; Li SY; Liu Y; Gonzalez FJ; Wang P; Ge GB
Bioorg Med Chem; 2021 Jan; 29():115851. PubMed ID: 33218896
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel indazole-acylsulfonamide hybrids as selective Mcl-1 inhibitors.
Wan Y; Li Y; Yan C; Wen J; Tang Z
Bioorg Chem; 2020 Nov; 104():104217. PubMed ID: 32911192
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors.
Liu L; Liu R; Yang X; Hou X; Fang H
Eur J Med Chem; 2020 Apr; 191():112142. PubMed ID: 32088497
[TBL] [Abstract][Full Text] [Related]
4. Design and Synthesis of Coumarin Derivatives as Novel PI3K Inhibitors.
Ma CC; Liu ZP
Anticancer Agents Med Chem; 2017; 17(3):395-403. PubMed ID: 26902599
[TBL] [Abstract][Full Text] [Related]
5. 1-Phenyl-1H-indole derivatives as a new class of Bcl-2/Mcl-1 dual inhibitors: Design, synthesis, and preliminary biological evaluation.
Xu G; Liu T; Zhou Y; Yang X; Fang H
Bioorg Med Chem; 2017 Oct; 25(20):5548-5556. PubMed ID: 28866374
[TBL] [Abstract][Full Text] [Related]
6. In silico approaches to identify novel myeloid cell leukemia-1 (Mcl-1) inhibitors for treatment of cancer.
Ren JX; Li CP; Zhou XL; Cao XS; Xie Y
J Biomol Struct Dyn; 2018 Jul; 36(9):2424-2435. PubMed ID: 28714799
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, stereochemical determination, molecular docking study, in silico pre-ADMET prediction and anti-proliferative activities of indole-pyrimidine derivatives as Mcl-1 inhibitors.
Lamie PF; Philoppes JN
Bioorg Chem; 2021 Nov; 116():105335. PubMed ID: 34509795
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
[TBL] [Abstract][Full Text] [Related]
9. Identification of Small-Molecule Inhibitors of the Antiapoptotic Protein Myeloid Cell Leukaemia-1 (Mcl-1).
Beekman AM; O'Connell MA; Howell LA
ChemMedChem; 2016 Apr; 11(8):840-4. PubMed ID: 26616140
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based Optimization of 3-Phenyl-
Li Y; Fan W; Gong Q; Tian J; Zhou M; Li Q; Uwituze LB; Zhang Z; Hong R; Wang R
J Med Chem; 2021 Jul; 64(14):10260-10285. PubMed ID: 34228434
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design, synthesis, and evaluation of Bcl-2/Mcl-1 dual inhibitors.
Zhu J; Wang Z; Guo Z; Zhang X; Song T; Guo Y; Ji T; Zhang Z
Arch Pharm (Weinheim); 2020 May; 353(5):e2000005. PubMed ID: 32175625
[TBL] [Abstract][Full Text] [Related]
12. New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: Synthesis, CDK2 inhibition, QSAR and molecular docking studies.
Abd El-Karim SS; Syam YM; El Kerdawy AM; Abdelghany TM
Bioorg Chem; 2019 May; 86():80-96. PubMed ID: 30685646
[TBL] [Abstract][Full Text] [Related]
13. Discovery of selective Mcl-1 inhibitors via structure-based design and structure-activity relationship analysis.
He N; Liu P; Wang Z; Guo Z; Yan X; Chen H; Zhang Z
Biochem Biophys Res Commun; 2019 May; 512(4):921-926. PubMed ID: 30928099
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.
Niu Q; Deng H; Zhang Z; Xu Q; Luan S; Huang M; Liu D; Zhao L
Bioorg Med Chem Lett; 2021 Sep; 47():128215. PubMed ID: 34153472
[TBL] [Abstract][Full Text] [Related]
15. Drimane Derivatives as the First Examples of Covalent BH3 Mimetics that Target MCL-1.
Daressy F; Malard F; Seguy L; Guérineau V; Apel C; Dumontet V; Robert A; Groo AC; Litaudon M; Bignon J; Desrat S; Malzert-Fréon A; Wiels J; Lescop E; Roussi F
ChemMedChem; 2021 Jun; 16(11):1788-1797. PubMed ID: 33665938
[TBL] [Abstract][Full Text] [Related]
16. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG
Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900
[TBL] [Abstract][Full Text] [Related]
17. 2-Aminobenzoxazole-appended coumarins as potent and selective inhibitors of tumour-associated carbonic anhydrases.
Fuentes-Aguilar A; Merino-Montiel P; Montiel-Smith S; Meza-Reyes S; Vega-Báez JL; Puerta A; Fernandes MX; Padrón JM; Petreni A; Nocentini A; Supuran CT; López Ó; Fernández-Bolaños JG
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):168-177. PubMed ID: 34894971
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors.
Wan Y; Wang J; Sun F; Chen M; Hou X; Fang H
Bioorg Med Chem; 2015 Dec; 23(24):7685-93. PubMed ID: 26620718
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of New Biscoumarin Derivatives, In Vitro Cholinesterase Inhibition, Molecular Modelling and Antiproliferative Effect in A549 Human Lung Carcinoma Cells.
Hudáčová M; Hamuľaková S; Konkoľová E; Jendželovský R; Vargová J; Ševc J; Fedoročko P; Soukup O; Janočková J; Ihnatova V; Kučera T; Bzonek P; Novakova N; Jun D; Junova L; Korábečný J; Kuča K; Kožurková M
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917200
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of coumarin analogs as novel LSD1 inhibitors.
Sun Y; Lv R; Wu T; Zhang X; Sun Y; Yan J; Zhang Z; Zhao D; Cheng M
Arch Pharm (Weinheim); 2022 Feb; 355(2):e2100311. PubMed ID: 34862974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
